The anatomic pathology market is expected to grow from US$ 22,800.20 million in 2022 to US$ 33,145.78 million by 2028; it is estimated to grow at a CAGR of 6.4% from 2022 to 2028.
Anatomic pathology is a significant part of the study and treatment of diseases. It is a broad field that includes decedent pathology, surgical pathology, cytopathology, neuropathology, and ophthalmic pathology. It is usually performed in medical laboratories of hospitals and diagnostic laboratories. The market growth is attributed to the increasing prevalence of cancer and other diseases and growing focus on personalized medicines. However, the lack of skilled professionals and stringent government regulations are hampering the market growth.
The anatomic pathology market is segmented on the basis of product and service, application, end user, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The report offers insights and in-depth analysis of the market, emphasizing various parameters such as market trends, technological advancements, market dynamics and the competitive landscape of leading global market players.
Strategic Insights
Lucrative Regions for Anatomic Pathology Market
Market Insights
Development of New Technologies and Launch of Products
There is a huge scope for the integration of machine learning (ML) and artificial intelligence (AI)-based systems in medical streams, including anatomic pathology. Several anatomic pathology laboratories are becoming increasingly aware of the benefits of digitization and AI in practice. Moreover, recent technological advancements and regulatory approvals are encouraging the digitalization of laboratories’ operations to improve the speed and accuracy of processes. Properly designed AI-based tools hold immense potential to improve workflow efficiency and diagnostic accuracy in pathology. AI technology can enhance the pathology imaging, which is enabling greater precision in diagnosis and leading to disease-specific treatment.
Digital pathology, a growing subfield within anatomical pathology, uses digital technologies to streamline data collection and management. It helps reduce risks to specimen samples and has the potential to accelerate enrolment in clinical trials. Moreover, it can reduce sample-to-result turnaround time and streamline the central pathology review process, thus offering opportunities to increase trial efficiency.
In 2018, Sakura Finetek USA, Inc. commercialized Accu-Cut SRM 300 LT, a manual microtome. This manual microtome with innovative features is designed to simplify the visualization of paraffin-embedded tissue samples and enable safer sectioning. The Accu-Cut SRM 300 LT has many exclusive user safety features that reduce the risk of accidental injuries associated with blade exposure. Various market players are focused on introducing innovative solutions. For instance, RadNet, an imaging service provider, and Hologic, a diagnostic product developer, collaborated to develop AI tools for breast health. Thus, the introduction of new technologies and products is likely to emerge as a significant trend in the anatomic pathology market during the forecast period.
Product and Service Insights
Based on product and service, the global anatomic pathology market is segmented into instruments, consumables, and services. The services segment held the largest market share in 2022; however, the instruments segment is anticipated to register the highest CAGR of 7.0% during the forecast period.
Application Insights
Based on application, the anatomic pathology market is segmented into disease diagnosis, drug discovery and development, and others. The disease diagnosis segment is likely to hold the largest share of the market in 2022; however, the drug discovery and development segment is anticipated to register the highest CAGR of 7.0% during the forecast period.
End User Insights
Based on end user, the anatomic pathology market is segmented into hospitals, research laboratories, diagnostic laboratories, and others. The others segment includes pharmaceutical and biotechnology companies and contract research organizations (CROs). The hospitals segment held the largest share of the market in 2022; however, the diagnostic laboratories segment is anticipated to register the highest CAGR of 7.0% during the forecast period.
Anatomic Pathology Market, by End User – 2022 and 2028
Product launches and mergers and acquisitions are the highly adopted strategies by the players operating in the global anatomic pathology market. A few of the recent key developments are listed below:
- In September 2021, Roche launched the Digital Pathology Open Environment to encourage software developers to collaborate to enhance patient outcomes and increase personalized healthcare through novel image analysis technologies.
- In May 2021, BioGenex launched CD8A, CD56, and CD163, the three primary immunohistochemistry (IHC) antibodies for cancer diagnosis.
- In August 2021, in the US, BD introduced a completely automated high-throughput diagnostic system that uses robotics and sample management software algorithms. The system created a benchmark in automation for infectious disease molecular testing in core laboratories and other centralized labs.
- In July 2021, BD announced the commercial launch of bdbiosciences.com web and e-commerce site, a completely "reimagined" digital marketplace to offer consumers and their procurement teams a better online purchase experience.
The COVID-19 pandemic and the disruption it caused in healthcare resources impacted every aspect of the diagnostics industry, including the anatomic pathology market. The shutdown of clinics, operation rooms, and physicians’ offices and the “stay-at-home” mandates across the globe severely affected the acquisition and submission of specimens for pathological evaluation. In 2020 and 2021, the number of patient visits to hospitals reduced significantly, despite emergency and OPD services being available in hospitals. Further, most hospitals invested their efforts and resources in diagnosing and treating COVID-19; as a result, many planned surgeries were canceled or delayed. Hence, various early cancer detection systems were deactivated, and most of autopsies were suspended. This situation hampered the medical care of patients with illnesses other than COVID-19, including patients with chronic diseases, oncology patients, or those awaiting organ transplantation. Consequently, the number of surgical pathology and cytology samples received in anatomic pathology labs was reduced.
Anatomic Pathology – Market Segmentation
Based on product and service, the global anatomic pathology market is segmented into instruments, consumables, and services. Based on application, the anatomic pathology market is segmented into disease diagnosis, drug discovery and development, and others. Based on end user, the anatomic pathology market is segmented into hospitals, research laboratories, diagnostic laboratories, and others. Based on geography, the market is segmented into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), Middle East & Africa (Saudi Arabia, South Africa, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America)
Company Profiles
- F. Hoffmann-La Roche Ltd.
- Danaher
- Hologic, Inc.
- Agilent Technologies, Inc.
- BioGenex
- Diapath S.p.A.
- Bio SB
- Merck KGaA
- BD
- PHC Holdings Corporation